ChangXin Memory Technologies (CXMT) now holds 8% of the global DRAM market, a milestone for the Chinese chipmaker. Its DRAM chips are priced 60% below those of established rivals. Apple is testing CXMT's memory for potential use in devices sold in China.
The 8% milestone
CXMT's market share has grown steadily, reaching 8% in recent months. The company, based in Hefei, China, has been ramping up production of DRAM chips used in smartphones, servers, and PCs. That puts it in direct competition with industry giants Samsung, SK Hynix, and Micron.
Analysts had not expected CXMT to hit that level so quickly. The company's aggressive pricing is a key factor. Its chips sell for 60% less than comparable products from rivals, a gap that pressures margins across the sector.
Pricing strategy
CXMT's low prices are not a temporary promotion. The company has built a cost structure that allows it to undercut competitors by a wide margin. That includes access to government subsidies and lower labor costs in China.
Rivals have responded by cutting their own prices, but they cannot match CXMT's discounts without hurting profitability. The price gap has made CXMT an attractive option for Chinese device makers looking to reduce costs.
Apple's evaluation
Apple is testing CXMT's DRAM for use in iPhones and other products destined for the Chinese market. The company has not confirmed any plans to adopt the chips, but testing is a necessary step before any potential deal.
If Apple does use CXMT memory, it would be a major win for the Chinese chipmaker. Apple is one of the world's largest buyers of DRAM, and a partnership could boost CXMT's share further. But the testing process is lengthy, and Apple has strict quality and reliability standards.
Apple already sources some components from Chinese suppliers, but memory chips have been dominated by Korean and U.S. firms. A shift to CXMT would reflect the growing capabilities of China's semiconductor industry.
No timeline has been given for Apple's decision. The testing could take months, and any deal would likely face scrutiny from regulators in the U.S. and elsewhere.
